Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects. (18th May 2020)
- Record Type:
- Journal Article
- Title:
- Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects. (18th May 2020)
- Main Title:
- Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
- Authors:
- Bánvölgyi, András
Anker, Pálma
Lőrincz, Kende
Kiss, Norbert
Márton, Dalma
Fésűs, Luca
Gyöngyösi, Nóra
Wikonkál, Norbert - Abstract:
- Abstract: Background: Smoothened receptor inhibitor vismodegib is indicated to treat locally advanced basal cell carcinoma (laBCC) and lesions in nevoid basal cell carcinoma syndrome (NBCCS). Methods: We treated 11 patients – including four NBCCS and seven laBCC patients – with vismodegib at our department. Results: Complete remission was achieved in three cases, without relapse after discontinuation. Two of the aforementioned patients had NBCCS, in their cases further treatment might be needed. Two patients showed improvement, but later passed away due to unrelated conditions. Two patients with laBCC initially showed remission, then the treatment was suspended due to side effects. After re-administration of the drug, loss of efficacy was observed. We did not observe therapy resistance in our NBCCS group. The rest of the patients showed good response to therapy, but have not reached full remission yet. The main side effects of vismodegib were muscle cramps, dysgeusia, nausea and alopecia. The frequency of adverse events did not show significant differences between the patient groups. Conclusions : Our results show that vismodegib therapy is effective in the treatment of BCC; however, side effects are often severe. Since the suspension of treatment can lead to therapy resistance, the management of side effects is of great importance.
- Is Part Of:
- Journal of dermatological treatment. Volume 31:Number 4(2020)
- Journal:
- Journal of dermatological treatment
- Issue:
- Volume 31:Number 4(2020)
- Issue Display:
- Volume 31, Issue 4 (2020)
- Year:
- 2020
- Volume:
- 31
- Issue:
- 4
- Issue Sort Value:
- 2020-0031-0004-0000
- Page Start:
- 387
- Page End:
- 398
- Publication Date:
- 2020-05-18
- Subjects:
- Basal cell carcinoma -- vismodegib -- Smo inhibitor -- side effects
Skin -- Diseases -- Treatment -- Periodicals
Skin Diseases -- drug therapy -- Periodicals
Skin Diseases -- therapy -- Periodicals
616.5 - Journal URLs:
- http://informahealthcare.com/loi/jdt ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/09546634.2019.1601155 ↗
- Languages:
- English
- ISSNs:
- 0954-6634
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4968.767000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13640.xml